Andrés Jérez

Dr. Andrés Jérez

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2024 in Journal of Clinical Oncology
Verified
Journal Article
Open access
CTCristina Astrid Tentori
Cristina Astrid Tentori
CGCaterina Gregorio
Caterina Gregorio
Marie RobinMarie Robin
Marie Robin
NGNico Gagelmann
Nico Gagelmann
CGCarmelo Gurnari
Carmelo Gurnari
FCFabio Ciceri
Fabio Ciceri
PURPOSE: Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only potentially curative treatment for patients with myelodysplastic syndromes (MDS). Several issues must be considered when evaluating the benefits and risks of HSCT for patients with MDS, with the timing of transplantation being a crucial question. Here, we aimed to develop and validate a decision support system to define the optimal timing of HSCT for patients with MDS on the basis of clinical and genomic information as provided by the Molecular International Prognostic Scoring System (IPSS-M). PATIENTS AND METHODS: We studied a retrospective population of 7,118 patients, stratified into training and validation cohorts. A decision strategy was built to estimate the average survival over an 8-year time horizon (restricted mean survival time [RMST]) for each combination of clinical and genomic covariates and to determine the optimal transplantation policy by comparing different strategies. RESULTS: Under an IPSS-M based policy, patients with either low and moderate-low risk benefited from a delayed transplantation policy, whereas in those belonging to moderately high-, high- and very high-risk categories, immediate transplantation was associated with a prolonged life expectancy (RMST). Modeling decision analysis on IPSS-M versus conventional Revised IPSS (IPSS-R) changed the transplantation policy in a significant proportion of patients (15% of patient candidate to be immediately transplanted under an IPSS-R–based policy would benefit from a delayed strategy by IPSS-M, whereas 19% of candidates to delayed transplantation by IPSS-R would benefit from immediate HSCT by IPSS-M), resulting in a significant gain-in-life expectancy under an IPSS-M–based policy ( P = .001). CONCLUSION: These results provide evidence for the clinical relevance of including genomic features into the transplantation decision making process, allowing personalizing the hazards and effectiveness of HSCT in patients with MDS.

Verified
Journal Article
Open access
PDF file
CECLAVERO Maria Esther
CLAVERO Maria Esther
JSJosé Manuel Sanchez-Maldonado
José Manuel Sanchez-Maldonado
AMAngelica Macauda
Angelica Macauda
RHRob ter Horst
Rob ter Horst
BSBelém Sampaio-Marques
Belém Sampaio-Marques
Juan SainzJuan Sainz
Juan Sainz
Multiple myeloma (MM) arises following malignant proliferation of plasma cells in the bone marrow, that secrete high amounts of specific monoclonal immunoglobulins or light chains, resulting in the massive production of unfolded or misfolded proteins. Autophagy can have a dual role in tumorigenesis, by eliminating these abnormal proteins to avoid cancer development, but also ensuring MM cell survival and promoting resistance to treatments. To date no studies have determined the impact of genetic variation in autophagy-related genes on MM risk. We performed meta-analysis of germline genetic data on 234 autophagy-related genes from three independent study populations including 13,387 subjects of European ancestry (6863 MM patients and 6524 controls) and examined correlations of statistically significant single nucleotide polymorphisms (SNPs; p < 1 × 10−9) with immune responses in whole blood, peripheral blood mononuclear cells (PBMCs), and monocyte-derived macrophages (MDM) from a large population of healthy donors from the Human Functional Genomic Project (HFGP). We identified SNPs in six loci, CD46, IKBKE, PARK2, ULK4, ATG5, and CDKN2A associated with MM risk (p = 4.47 × 10−4−5.79 × 10−14). Mechanistically, we found that the ULK4rs6599175 SNP correlated with circulating concentrations of vitamin D3 (p = 4.0 × 10−4), whereas the IKBKErs17433804 SNP correlated with the number of transitional CD24+CD38+ B cells (p = 4.8 × 10−4) and circulating serum concentrations of Monocyte Chemoattractant Protein (MCP)-2 (p = 3.6 × 10−4). We also found that the CD46rs1142469 SNP correlated with numbers of CD19+ B cells, CD19+CD3− B cells, CD5+IgD− cells, IgM− cells, IgD−IgM− cells, and CD4−CD8− PBMCs (p = 4.9 × 10−4−8.6 × 10−4) and circulating concentrations of interleukin (IL)-20 (p = 0.00082). Finally, we observed that the CDKN2Ars2811710 SNP correlated with levels of CD4+EMCD45RO+CD27− cells (p = 9.3 × 10−4). These results suggest that genetic variants within these six loci influence MM risk through the modulation of specific subsets of immune cells, as well as vitamin D3−, MCP-2−, and IL20-dependent pathways.

5 January 2016 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
JMJulia Muñoz‐Ballester
Julia Muñoz‐Ballester
TCTzu-Hua Chen-Liang
Tzu-Hua Chen-Liang
ALAna María Hurtado López
Ana María Hurtado López
IHInmaculada Heras
Inmaculada Heras
FAFelipe de Arriba
Felipe de Arriba
AJAndrés Jérez
Andrés Jérez

5 March 2012 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
YSYuka Sugimoto
Yuka Sugimoto
MSMikkael A Sekeres
Mikkael A Sekeres
HMHideki Makishima
Hideki Makishima
FTFabiola Traina
Fabiola Traina
Valeria VisconteValeria Visconte
Valeria Visconte
JMJaroslaw P. Maciejewski
Jaroslaw P. Maciejewski
Background: While lenalidomide (LEN) shows high efficacy in myelodysplastic syndromes (MDS) with del[5q], responses can be also seen in patients presenting without del[5q]. We hypothesized that improved detection of chromosomal abnormalities with new karyotyping tools may better predict response to LEN. Design and methods: We have studied clinical, molecular and cytogenetic features of 42 patients with MDS, myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes and secondary acute myeloid leukemia (sAML) without del[5q] by metaphase cytogenetics (MC) who underwent therapy with LEN. Results: Fluorescence in situ hybridization (FISH) or single nucleotide polymorphism array (SNP-A)-based karyotyping marginally increased the diagnostic yield over MC, detecting 2/42 (4.8%) additional cases with del[5q], one of whom were responded to LEN. Responses were more often observed in patients with a normal karyotype by MC (60% vs abnormal MC; 17%, p = .08) and those with gain of chromosome 8 material by either of all 3 karyotyping methods (83% vs all other chromosomal abnormalities; 44% p = .11). However, 5 out of those 6 patients received combined LEN/AZA therapy and it may also suggest those with gain of chromosome 8 material respond well to AZA. The addition of FISH or SNP-A did not improve the predictive value of normal cytogenetics by MC. Mutational analysis of TET2, UTX, CBL, EZH2, ASXL1, TP53, RAS, IDH1/2, and DNMT-3A was performed on 21 of 41 patients, and revealed 13 mutations in 11 patients, but did not show any molecular markers of responsiveness to LEN. Conclusions: Normal karyotype and gain of chromosome 8 material was predictive of response to LEN in non-del[5q] patients with myeloid malignancies.

13 November 2018 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MFMariana Fernández‐Caballero
Mariana Fernández‐Caballero
DSDiego Salmerón
Diego Salmerón
MCMaría Dolores Chirlaque
María Dolores Chirlaque
TCTzu-Hua Chen-Liang
Tzu-Hua Chen-Liang
ALAna María Hurtado López
Ana María Hurtado López
FAFelipe De Arriba
Felipe De Arriba

27 September 2018 in Transfusion
Verified
Journal Article
Closed access
PDF file
PIPastora Iniesta
Pastora Iniesta
NRNuria Revilla
Nuria Revilla
TCTzu-Hua Chen-Liang
Tzu-Hua Chen-Liang
ALAna María Hurtado López
Ana María Hurtado López
VVVicente Vicente
Vicente Vicente
MLMaria L Lozano
Maria L Lozano